This Pharma Stock Declines 4.86 per cent; Board Approves Rs 570 Crore Fundraise, Know the Stock Outlook Here
This Pharma Stock Declines 4.86 per cent; Board Approves Rs 570 Crore Fundraise, Know the Stock Outlook Here

This Pharma Stock Declines 4.86 per cent; Board Approves Rs 570 Crore Fundraise, Know the Stock Outlook Here

The Board of Directors approved the issuance of commercial papers worth Rs 570 crore on a private placement basis

Abhishek Wani Article rating: 3.3

The Board of Directors approved the issuance of commercial papers worth Rs 570 crore on a private placement basis

Aditya Birla Group Company Announces Fundraising via Promoter and QIP Ahead of Major Business Spinoff
Aditya Birla Group Company Announces Fundraising via Promoter and QIP Ahead of Major Business Spinoff

Aditya Birla Group Company Announces Fundraising via Promoter and QIP Ahead of Major Business Spinoff

Promoter participation at a 17.5 per cent premium over the previous day's closing price reflects strong confidence in the company's growth potential.

Abhishek Wani Article rating: 4.2


Promoter participation at a 17.5 per cent premium over the previous day's closing price reflects strong confidence in the company's growth potential.

RSS

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR